CBA 研讨会系列:基因编辑: 机遇与挑战(3月2日)

Posted By on February 13, 2019

美国华人生物医药科技协会 (CBA)

约翰霍普金斯大学中国学生学者联合会 (JHU CSSA)

2019年 CBA 研讨会系列-3月

Genome Editing: Opportunities and Challenges

基因编辑: 机遇与挑战

2019年3月2日,  (星期六上午9:30至下午 3时)

Mudd 26 at Johns Hopkins University,

3400 N Charles St., Baltimore, MD 21218

CBA 研讨会系列

立即(通过QR code)注册以预订座位

(公众 $5.00, CBA,  NIH, JHU-CSSA, ASQ509会员免费)

CBA 研讨会系列

2018年11月,人类史上首例CRISPR双胞胎婴儿在中国的出生,于全世界范围引起了轩然大波,使临床应用中的基因组编辑及其伦理问题再次成为一个热门话题。尽管基因组编辑承载着改善人类健康和治愈疾病的希望,但它也再次激起了人们对这把双刃剑具有争议性的另一面的担忧。我们,真的准备好了吗?

 

在本次研讨会上, 來自NIH, NCI, NIST, Johns Hopkins University, Pacbio and MIT Technology Review等世界顶级研究团队的专家将就以下话题进行讨论:

  1. 基因编辑于科学和临床的应用。
  2. 基因编辑的挑战以及安全问题。
  3. 人类细胞基因编辑的伦理問題。

*上、下午分别设有自由讨论时间。

 

午餐时间和研讨会结束后都为社交时间, 主办机构将提供免费茶点。

CBA 研讨会系列

CBA 研讨会系列

研讨会的日程将刊於 CBA 活动页面上。

 

 

 

议程 (draft)

9:00 am-9:30am 登记及社交
9:30 am-9:40am 开幕致辞(CBA president and CSSA President)
9:40 am-9:50 am 活动简介及各种通告
 

9:50-11:05am

基础及转化科研机会

驾驭基因组编辑技术来高精度的理解生物学Raj Chari, Ph.D., Director, Genome Modification Core NCI/FNLCR 25分钟

美国国立卫生研究院体细胞基因组编辑计划介绍Mary Ellen Perry, Ph.D., Program Leader, NIH  25分钟

美国国家标准技术研究所基因组编辑计划介绍Samantha Maragh, Ph.D., Leader, Genome Editing Program, NIST 25分钟

11:05 am-11:15 am 小憩
11:15 am-11:40 am 检测基因组编辑产物Emily Hatas, Ph.D., Sr. Director, Business Development, PacBio 25分钟
11:40 am-12:10pm 上午讨论环节 (基础及转化科研机会

和临床影响)

(上午讨论主持人:杨洪钧博士)

12:10 pm-1:00 pm 午休

 

1:00pm-2:00pm 伦理/道德方面的挑战

“深入首例CRISPR 婴儿—中国处于干细胞生物学和基因编辑的前沿” Antonio Regalado, Ph.D., Senior Editor, MIT Technology Review 25分钟

题目待定; Debra Mathews, Ph.D., MA, Assistant Director for Science Programs, Johns Hopkins Berman Institute of Bioethics 25 分钟

2:00pm-2:30pm 下午讨论环节(监管和道德挑战)

(由下午嘉宾和上午余下嘉宾共同领导)

2:30pm-3:00pm 总结和休会

 

 

 

 

Raj Chari

 

Director,

Genome Modification Core, Frederick National Lab for Cancer Research

Raj Chari

Dr. Raj Chari obtained his bachelor’s degrees in both biochemistry and computer science at the University of British Columbia. He then went onto doing his PhD under the supervision of Dr. Wan Lam at the British Columbia Cancer Research Centre, specializing in lung cancer genomics. Subsequently, he did his postdoctoral fellowship at Harvard Medical School with Dr. George Church where he helped develop genome engineering technologies. After briefly working in industry at AbVitro and Juno Therapeutics, he is now the director of the Genome Modification Core at the Frederick National Lab for Cancer Research.

Mary Ellen Perry, Ph.D.

Mary Ellen Perry, Ph.D.

Program Leader

OD/NIH

Since 2007, Dr. Mary Ellen Perry has been a program leader in the Office of Strategic Coordination, overseeing the development, implementation and assessment of several cutting-edge programs. Prior to joining the Office of the Director, Dr. Perry was a program director for the National Cancer Institute (NCI), where she oversaw a grant portfolio focused on research in aspects of molecular biology of particular relevance to cancer. Until 2016, Dr. Perry also maintained a laboratory at the NCI, employing genetically engineered mice to explore the relationship between development and cancer. Her background in cancer research is founded on a Ph.D. in biochemistry from the University of North Carolina and post-doctoral fellowships at Princeton University and the Imperial Cancer Research Fund, London (now part of Cancer Research, UK). For seven years, she led a cancer research laboratory at the University of Wisconsin-Madison, where she succeeded in winning two NIH grants, publishing several papers, and training five Ph.D. students, two of whom are now professors.

Samantha Maragh, Ph.D.

 

Genome Editing Program Leader

NIST

Samantha Maragh, Ph.D.

Dr. Samantha Maragh Leads the Genome Editing Program at the National Institute of Standards and Technology (NIST).  This program has a primary focus on measurements and assay qualification to support genome editing applications  with emphasis on gene therapy applications.  Included in this program is the newly launched NIST Genome Editing Consortium, which is a public-private partnership to bring together government, industry and academia to address shared pre-competitive technical measurement and standards challenges within the genome editing community.  Samantha also participates on representing the U.S. as a technical expert to the International Standards Organizations Technical Committee on Biotechnology (ISO TC 276).  She is currently a U.S. liaison representing the interests and expertise of the U.S. on standards relating to nucleic acids measurements. Samantha received her M.S. in Biotechnology from Johns Hopkins University, and her Ph.D. in Human Genetics & Molecular Biology from the Johns Hopkins School of Medicine.

 

Antonio Regalado

Senior Editor

Antonio Regalado

MIT Technology Review

Antonio is the senior editor for biomedicine for MIT Technology Review. He looks for stories about how technology is changing medicine and biomedical research. Before joining MIT Technology Review in July 2011, he lived in São Paulo, Brazil, where he wrote about science, technology, and politics in Latin America for Science and other publications. From 2000 to 2007, he was the science reporter at the Wall Street Journal. Antonio has an undergraduate degree in physics from Yale and a masters in science journalism from New York University.

Emily Hatas

Senior Director

Emily Hatas

Pacific Biosciences

Emily Hatas has been with PacBio for more than four years, most recently as the Senior Director of Business Development, leading several commercial initiatives in agricultural and human-biomedical research. Prior to this, she served as business development manager for KeyGene, a Dutch agricultural biotech company. She studied plant biology at the University of Wisconsin-Madison before continuing on to business school.